Skip to main content

OW29 documents

20/06/2025
Panitumumab supplementary tables CIC removed for website OW29
20/06/2025
Panitumumab rechallenge mCRC ESR CIC removed for website OW29
20/06/2025
Panitumumab RASWT mCRC final recommendation with start_stop criteria (OW29)
20/06/2025
OWMAG decision rationale panitumumab mCRC final OW29
20/06/2025
EqHIA Panitumumab for RASWT mCRC assessment 2025 OW29
20/06/2025
Appendix 2.b. Cost of regorafenib followed by best supportive care and Appendix 2.c. Cost of best supportive care for fifth-line 
20/06/2025
Appendix 2.a. Cost of trifluridine-tipiracil and bevacizumab followed by best supportive care
20/06/2025
Appendix 1 PRISMA flow diagram (43)
20/06/2025
Table 13. Budget impact for four months panitumumab as fourth line treatment
20/06/2025
Table 12. Budget impact for four months panitumumab as third line treatment
20/06/2025
Table 11. Net resource costs for upper and lower patient number estimates for panitumumab and comparator treatments
20/06/2025
Table 10. Cost of panitumumab and comparators in Wales (per patient)
20/06/2025
Table 9. Severity modifier considerations for One Wales Medicines Assessment Group (OWMAG)
20/06/2025
Table 8. Examples of medicine acquisition costs 
20/06/2025
Table 7. Potential QALY by treatment line 
20/06/2025
Table 6. Threshold analysis
20/06/2025
Table 5. Fourth-line and Fifth-line cost consequence analyses
20/06/2025
Table 4. Base case analysis 
20/06/2025
Table 3. Progression free survival, overall survival and adverse events
20/06/2025
Table 2. Comparator costs
Follow AWTTC: